Investigational drugs in phase II clinical trials for primary biliary cholangitis.

about

[Modern treatment of primary biliary cholangitis].Bile acid signaling and bariatric surgery

P2860

Q50130002-0F525F7C-A3B9-4175-9929-C420CF06E261 Q57124605-4D7D0479-4DE7-43D1-AF0B-C02EA00C540D

P2860

Investigational drugs in phase II clinical trials for primary biliary cholangitis.

Item

http://www.wikidata.org/entity/Q53098304

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Investigational drugs in phase II clinical trials for primary biliary cholangitis.

@en

Investigational drugs in phase II clinical trials for primary biliary cholangitis.

@nl

type

Item

label

Investigational drugs in phase II clinical trials for primary biliary cholangitis.

@en

Investigational drugs in phase II clinical trials for primary biliary cholangitis.

@nl

prefLabel

Investigational drugs in phase II clinical trials for primary biliary cholangitis.

@en

Investigational drugs in phase II clinical trials for primary biliary cholangitis.

@nl

P1476

Investigational drugs in phase II clinical trials for primary biliary cholangitis.

@en

P2093

Keith D Lindor

http://www.w3.org/2001/XMLSchema#string

Marina G Silveira

http://www.w3.org/2001/XMLSchema#string

P2860

Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants

Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review

A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis

Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis

Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol

Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys.

The CD40/CD40L costimulatory pathway in inflammatory bowel disease

Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis.

Genome-Wide Association Studies in Primary Biliary Cirrhosis.

Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.

P304

1115-1121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2017.1371135

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28836457

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

cholangitis

Investigational drugs in phase II clinical trials for primary biliary cholangitis.

about

P2860

P2860

Investigational drugs in phase II clinical trials for primary biliary cholangitis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921